Tissue expression of LC3B autophagy marker as a potential biomarker of prostate cancer recurrence after treatment with high-intensity focused ultrasound (pilot study)

Author:

Voronina E. S.1ORCID,Fomkin R. N.1ORCID,Bucharskaya A. B.1ORCID,Palatova T. V.1ORCID,Maslyakova G. N.1ORCID,Fomkina O. A.1ORCID

Affiliation:

1. Saratov State Medical University named after V.I. Razumovsky, Ministry of Health of Russia

Abstract

Background. The role of autophagy markers in prostate tumor recurrence has not been sufficiently investigated. We hypothesized that autophagy activation may be one mechanism by which prostate cancer cells survive exposure to high-intensity focused ultrasound (HIFU).Aim. To compare tissue expression of autophagic LC3B marker in prostate biopsies before and after treatment of localized prostate cancer by HIFU ablation.Materials and methods. 45 patients with localized morphologically confirmed prostate cancer were examined: group 1 – 25 patients of 65.6 ± 8.4 years without signs of recurrence or progression of the disease; group 2 – 20 patients of 67.5 ± 7.9 years with tumor recurrence proven during morphological examination. Immunohistochemical examination was performed by streptavidin-biotin method. In all cases, Anti-LC3B antibody ab48394 was used. The reaction results were quantified using the Histochemical score (Hs) system.Results. Prior to treatment, all patients of group 1 showed moderate cytoplasmic expression (Hs = 111 [111; 115]) of antibodies against LC3B in prostate adenocarcinoma cells, 5 % of patients – weak cytoplasmic expression in muscle connective stromal cells (Hs = 47 [43; 50]), 10 % of patients – weak positive LC3B reaction in the vessel wall (Hs = 28 [20; 35]). After treatment, the expression of LC3B in adenocarcinoma cells became negative, in the cytoplasm of muscle connective stromal cells weak (Hs = 75 [67.5; 80.0]), in the endothelium of the vascular wall even weaker (Hs = 55 [45.5; 60.0]) (p <0.001). Prior to treatment in group 2, LC3B expression in tumor tissue was moderate in 89 % of patients (Hs = 151.5 [137.5; 160.0]), weak in muscle connective stromal cells in 12 % of patients (Hs = 44 [35; 51.5]), and weak in the vascular wall in 5 % of patients (Hs = 30 [25; 35]). After treatment, LC3B expression in adenocarcinoma cells became pronounced (Hs = 260 [250; 285]), in muscle connective stromal cells – moderate (Hs = 118 [100; 130]), in the vascular wall – weak (Hs = 45 [30; 55]) (p <0.001). There was a significant correlation between tumor recurrence and LC3B overexpression (r = 0.51; p <0.001).Conclusion. The development of prostate cancer recurrence is associated with increased expression of autophagic LC3B protein. Increased LC3B expression, which is interpreted as evidence of autophagy activation and correlates with the risk of disease progression, is used by the tumor as an oncogenic advantage.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference28 articles.

1. Kaprin A.D., Alekseev B.Ya., Matveev V.B. et al. Prostate cancer. Clinical recommendations. Sovremennaya onkologiya = Journal of Modern Oncology 2021;23(2):211–47. (In Russ.). DOI: 10.26442/18151434.2021.2.200959

2. Avraamova S.T. Preoperative and intraoperative diagnosis of prostate cancer using Raman luminescence spectroscopy. Dis. … candidate of medical sciences. Moscow, 2021. 24 p. (In Russ.).

3. Popkov V.M., Fomkin R.N., Blyumberg B.I. Possibilities of predicting prostate cancer recurrence after HIFU ablation using mathematical modeling. Saratovskiy nauchno-meditsinskiy zhurnal = Saratov Journal of Medical Scientific Research 2013;9(2):314–20. (In Russ.).

4. Lepor G. Is there a place for minimally invasive prostate cancer treatment technologies? Eksperimental’naya i klinicheskaya urologiya = Experimental and Clinical Urology 2011;(2–3):12–4. (In Russ.).

5. Lyovin V.P. Clinical, morphological and immunohistochemical characteristics of prostate adenocarcinoma under HIFU therapy. Dis. … candidate of medical sciences. Moscow, 2019. 23 p. (In Russ.).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3